Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species

Jensen L, Helleberg H, Roffel A, van Lier JJ, Bjørnsdottir I, Pedersen PJ, Rowe E, Derving Karsbøl J, Pedersen ML. European Journal of Pharmaceutical Sciences 2017

Document identifier
CEI-BR-053
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Jensen L, Helleberg H, Roffel A, van Lier JJ, Bjørnsdottir I, Pedersen PJ, Rowe E, Derving Karsbøl J, Pedersen ML
Title
Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
Source
European Journal of Pharmaceutical Sciences
Year
2017
Volume, issue, pages
104:31–41
Digital object identifier
10.1016/j.ejps.2017.03.020
PubMed identifier
28323117
Record type
Journal article
Institute identifier
CEI-BR-053

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: SemaglutideCompound monograph
1 citing document.

§1.3Subject tags

semaglutide adme pharmacokinetics

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.